Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Liabilities: 2022-2025

Historic Total Liabilities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $662.8 million.

  • Phathom Pharmaceuticals' Total Liabilities rose 15.44% to $662.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $662.8 million, marking a year-over-year increase of 15.44%. This contributed to the annual value of $631.9 million for FY2024, which is 29.86% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Total Liabilities stood at $662.8 million for Q3 2025, which was up 1.03% from $656.1 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Total Liabilities high stood at $662.8 million for Q3 2025, and its period low was $111.0 million during Q1 2022.
  • In the last 3 years, Phathom Pharmaceuticals' Total Liabilities had a median value of $553.2 million in 2024 and averaged $494.4 million.
  • Data for Phathom Pharmaceuticals' Total Liabilities shows a peak YoY skyrocketed of 125.37% (in 2024) over the last 5 years.
  • Phathom Pharmaceuticals' Total Liabilities (Quarterly) stood at $239.6 million in 2022, then skyrocketed by 103.07% to $486.6 million in 2023, then increased by 29.86% to $631.9 million in 2024, then grew by 15.44% to $662.8 million in 2025.
  • Its Total Liabilities stands at $662.8 million for Q3 2025, versus $656.1 million for Q2 2025 and $632.6 million for Q1 2025.